Floatz logo

AMMONIA N-13

Autonomic Failure

National Institute of Neurological Disorders and Stroke (NINDS)Small moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Autonomic Failure cohort.

Asset / SponsorPhaseRating
Entacapone
Daniel Claassen
Phase 1/2CCC
carbidopa
Daniel Claassen
Phase 1/2CCC
Droxidopa
Vanderbilt University Medical Center
Phase 1/2CCC
Midodrine
Vanderbilt University Medical Center
Phase 1CCC
Fezolinetant
Shehzad Basaria, M.D.
Phase 2CCC

View all 12 →

Same molecule, other indications

AMMONIA N-13 is also rated in:

sickle cell diseaseDormant
CCC
Indicative ·
48 / 100
View asset →
pure autonomic failureDormant
D
Indicative ·
30 / 100
View asset →
multiple system atrophyDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →